Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2)
Abstract
This work continues a series of recently published studies that employ recombinant single-domain antibody (sdAb, or nanobody®) generation technologies to battle viruses by a passive immunization approach. As a proof of principle, we describe a modified technique to efficiently generate protective molecules against a particular strain of influenza virus within a reasonably short period of time. This approach starts with the immunization of a camel (Camelus bactrianus) with the specified antigen-enriched material presented in as natural a form as possible. An avian influenza virus A/Mallard/Pennsylvania/10218/84 (H5N2) adapted for mice was used as a model source of antigens for both the immunization and phage display-based selection procedures. To significantly increase activities of initially selected monovalent single-domain antibodies, we propose a new type of sdAb formatting that involves the addition of a special type of coiled-coil sequence, the isoleucine zipper domain (ILZ). Presumably, the ILZ-containing peptides adopt trimeric parallel conformations. After the formatting, the biological activities (virus neutralization) of the initially selected anti-influenza virus (H5N2) sdAbs were significantly increased. Intraperitoneal or intranasal administration of the formatted sdAb at 2h before or 24h after viral challenge specifically protects mice from lethal infection with influenza virus. We hope that the described approach combined with the selection focused on particular conservative epitopes will lead to the generation of sdAb-based molecules protective against a broad spectrum of influenza virus subtypes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
VNAs offer some advantages over classical antibodies such as ease to engineer, improved heat and pH stability, and better tissue penetration.
“In general, VNAs offer some advantages over classical antibodies such as ease to engineer, improved heat and pH stability, and better tissue penetration (Hamers‐Casterman et al, 1993; van der Linden et al, 1999; Tillib et al, 2013).”
From mRNA mediates passive vaccination against infectious agents, toxins, and tumors (2017) · cites this paper as Tillib et al, 2013
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961 · see citing works
A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
REED, L. J., & Muench, H. (1938) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a118408 · Cited by 20,341 · see citing works
A simple method of estimating 50 per cent end points
Muench, H. (1938) · Medical Entomology and Zoology · Cited by 8,377 · see citing works
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241 · see citing works
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution
Wilson, I. A., Skehel, J. J., & Wiley, D. C. (1981) · Nature · doi:10.1038/289366a0 · Cited by 2,535 · see citing works
A Switch Between Two-, Three-, and Four-stranded Coiled Coils in GCN4 Leucine Zipper Mutants
Harbury, P. B., Zhang, T., Kim, P. S., & Alber, T. (1993) · Science · doi:10.1126/science.8248779 · Cited by 1,490 · see citing works
Friguet, B., Chaffotte, A. F., Djavadi‐Ohaniance, L., & Goldberg, M. E. (1985) · Journal of Immunological Methods · doi:10.1016/0022-1759(85)90044-4 · Cited by 1,235 · see citing works
Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011) · Science · doi:10.1126/science.1205669 · Cited by 1,203 · see citing works
Sui, J., Hwang, W. C., Perez, S., Ge, W., Aird, D. R., Chen, L., Santelli, E., Stec, B., Cadwell, G., Ali, M., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1566 · Cited by 1,132 · see citing works
Evidence That the Leucine Zipper Is a Coiled Coil
O’Shea, E. K., Rutkowski, R., & Kim, P. S. (1989) · Science · doi:10.1126/science.2911757 · Cited by 870 · see citing works
A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses
Ekiert, D. C., Friesen, R. H. E., Bhabha, G., Kwaks, T., Jongeneelen, M. A. C., Yu, W., Ophorst, C., Cox, F., Korse, H. J. W. M., Brandenburg, B., et al. (2011) · Science · doi:10.1126/science.1204839 · Cited by 823 · see citing works
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809 · see citing works
Greenberg, A. S., Avila, D. W., Hughes, M. K., Hughes, A. L., McKinney, E. C., & Flajnik, M. F. (1995) · Nature · doi:10.1038/374168a0 · Cited by 783 · see citing works
Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies
Ghahroudi, M. A., Desmyter, A., Wyns, L., HAMERS, R., & Muyldermans, S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01062-4 · Cited by 775 · see citing works
Targeting and tracing antigens in live cells with fluorescent nanobodies
Rothbauer, U., Zolghadr, K., Tillib, S. V., Nowak, D., Schermelleh, L., Gahl, A., Backmann, N., Conrath, K., Muyldermans, S., Cardoso, M. C., et al. (2006) · Nature Methods · doi:10.1038/nmeth953 · Cited by 715 · see citing works
Self-citationMolecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
Genst, E. D., Silence, K., Decanniere, K., Conrath, K., Loris, R., Kinne, J., Muyldermans, S., & Wyns, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505379103 · Cited by 681 · see citing works
Vincke, C., Loris, R., Saerens, D., Martínez‐Rodríguez, S., Muyldermans, S., & Conrath, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806889200 · Cited by 577 · see citing works
Camelid immunoglobulins and nanobody technology
Muyldermans, S., Baral, T. N., Retamozo, V. C., BAETSELIER, P. D., Genst, E. D., Kinne, J., Leonhardt, H., Magez, S., Nguyen, V. K., Revets, H., et al. (2008) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2008.10.299 · Cited by 535 · see citing works
Self-citationSingle domain antibodies: promising experimental and therapeutic tools in infection and immunity
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juárez‐Moreno, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., Scheuplein, F., et al. (2009) · Medical Microbiology and Immunology · doi:10.1007/s00430-009-0116-7 · Cited by 516 · see citing works
Whittle, J. R. R., Zhang, R., Khurana, S., King, L. R., Manischewitz, J. F., Golding, H., Dormitzer, P. R., Haynes, B. F., Walter, E. B., Moody, M. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111497108 · Cited by 439 · see citing works
Trimerization of a yeast transcriptional activator via a coiled-coil motif
Sorger, P. K., & Nelson, H. C. M. (1989) · Cell · doi:10.1016/0092-8674(89)90604-1 · Cited by 376 · see citing works
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Roovers, R. C., Laeremans, T., Huang, L., Taeye, S. D., Verkleij, A. J., Revets, H., de Haard, H., & Henegouwen, P. M. P. V. B. E. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0180-4 · Cited by 348 · see citing works
β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae
Conrath, K., Lauwereys, M., Galleni, M., Matagne, A., Frère, J., Kinne, J., Wyns, L., & Muyldermans, S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2807-2812.2001 · Cited by 348 · see citing works
Coppieters, K. T., Dreier, T., Silence, K., de Haard, H., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., de Wiele, C. V., Staelens, L., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21827 · Cited by 303 · see citing works
Conrath, K., Lauwereys, M., Wyns, L., & Muyldermans, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007734200 · Cited by 301 · see citing works
Efficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies
Stijlemans, B., Conrath, K., Cortez‐Retamozo, V., Xong, H. V., Wyns, L., Senter, P. D., Revets, H., BAETSELIER, P. D., Muyldermans, S., & Magez, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307341200 · Cited by 277 · see citing works
Krause, J. C., Tsibane, T., Tumpey, T. M., Huffman, C. J., Basler, C. F., & Crowe, J. E. (2011) · Journal of Virology · doi:10.1128/jvi.00700-11 · Cited by 204 · see citing works
Hultberg, A., Temperton, N. J., Rosseels, V., Koenders, M., González-Pajuelo, M., Schepens, B., Ibañez, L. I., Vanlandschoot, P., Schillemans, J. P., Saunders, M. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017665 · Cited by 195 · see citing works
Zhang, J., Tanha, J., Hirama, T., Khieu, N. H., To, R., Tong-Sevinc, H., Stone, E., Brisson, J., & MacKenzie, C. R. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.09.034 · Cited by 171 · see citing works
Functional heavy-chain antibodies in camelidae
Nguyen, V. K., Desmyter, A., & Muyldermans, S. (2001) · Advances in immunology · doi:10.1016/s0065-2776(01)79006-2 · Cited by 165 · see citing works
Nuttall, S. D., Krishnan, U. V., Hattarki, M. K., Gori, R. D., Irving, R. A., & Hudson, P. J. (2001) · Molecular Immunology · doi:10.1016/s0161-5890(01)00057-8 · Cited by 158 · see citing works
Saerens, D., Kinne, J., Bosmans, E., Wernery, U., Muyldermans, S., & Conrath, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409292200 · Cited by 148 · see citing works
Nanobodies®: New ammunition to battle viruses
Vanlandschoot, P., Stortelers, C., Beirnaert, E., Ibañez, L. I., Schepens, B., Depla, E., & Saelens, X. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.09.002 · Cited by 137 · see citing works
A bispecific nanobody to provide full protection against lethal scorpion envenoming
Hmila, I., Saerens, D., Abderrazek, R. B., Vincke, C., Abidi, N., Benlasfar, Z., Govaert, J., Ayeb, M. E., Bouhaouala‐Zahar, B., & Muyldermans, S. (2010) · The FASEB Journal · doi:10.1096/fj.09-148213 · Cited by 125 · see citing works
Nanobodies With In Vitro Neutralizing Activity Protect Mice Against H5N1 Influenza Virus Infection
Ibañez, L. I., Filette, M. D., Hultberg, A., Verrips, T. C., Temperton, N. J., Weiss, R. A., Vandevelde, W., Schepens, B., Vanlandschoot, P., & Saelens, X. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq168 · Cited by 116 · see citing works
Lo, C.-Y., Wu, Z.-Q., Misplon, J. A., Price, G. E., Pappas, C., Kong, W., Tumpey, T. M., & Epstein, S. L. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.02.047 · Cited by 80 · see citing works
Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens
Saerens, D., Stijlemans, B., Baral, T. N., Thi, G. T. N., Wernery, U., Magez, S., BAETSELIER, P. D., Muyldermans, S., & Conrath, K. (2007) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.10.005 · Cited by 68 · see citing works
Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif
Shiraishi, T., Suzuyama, K., Okamoto, H., Mineta, T., Tabuchi, K., Nakayama, K., Shimizu, Y. I., Tohma, J., Ogihara, T., Naba, H., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.098 · Cited by 62 · see citing works
Current Trends in Monoclonal Antibody Development and Manufacturing
Shire, S. J., Gombotz, W. R., Bechtold-Peters, K., & Andya, J. D. (2009) · Springer eBooks · doi:10.1007/978-0-387-76643-0 · Cited by 58 · see citing works
“Camel nanoantibody” is an efficient tool for research, diagnostics and therapy
Tillib, S. V. (2011) · Molecular Biology · doi:10.1134/s0026893311010134 · Cited by 52 · see citing works
Self-citationMarco, D. D., Clementi, N., Mancini, N., Solforosi, L., Moreno, G. J., Sun, X., Tumpey, T. M., Gubareva, L. V., Mishin, V. P., Clementi, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034415 · Cited by 51 · see citing works
Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design
Kaminski, D. A. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00076 · Cited by 38 · see citing works
Characterization of adaptation of an avian influenza A (H5N2) virus to a mammalian host.
Smirnov, Y. A., Lipatov, A. S., van Beek, R., Калмановна, Г. А., Osterhaus, A. D. M. E., & Claas, E. C. J. (2000) · PubMed · Cited by 32 · see citing works
Yamashita, A., Kawashita, N., Kubota‐Koketsu, R., Inoue, Y., Watanabe, Y., Ibrahim, M. S., Ideno, S., Yunoki, M., Okuno, Y., Takagi, T., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.031 · Cited by 22 · see citing works
Tillib, S. V., Ivanova, T. I., & Vasilev, L. A. (2010) · Acta Naturae · doi:10.32607/20758251-2010-2-3-85-93 · Cited by 18 · see citing works
Self-citationNanobodies, Single-Domain Antigen-Binding Fragments of Camelid Heavy-Chain Antibodies
Ghassabeh, G. H., Muyldermans, S., & Saerens, D. (2009) · Springer eBooks · doi:10.1007/978-0-387-76643-0_3 · Cited by 11 · see citing works
Tillib, S. V., Ivanova, T. I., Lyssuk, E. Y., Larin, S. S., Кибардин, А. В., Korobko, E. V., Вихрева, П. Н., Gnuchev, N. V., Georgiev, G. P., & Korobko, I. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912060132 · Cited by 7 · see citing works
Self-citationAffinity Measurements by Band Shift and Competition ELISA
Bumke, M. A., & Neri, D. (2001) · Springer eBooks · doi:10.1007/978-3-662-04605-0_28 · Cited by 3 · see citing works
Flagged first, then by citations
3 of the 51 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 470 · see citing works
mRNA mediates passive vaccination against infectious agents, toxins, and tumors
Thran, M., Mukherjee, J., Pönisch, M., Fiedler, K., Thess, A., Mui, B. L., Hope, M. J., Tam, Y. K., Horscroft, N., Heidenreich, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707678 · Cited by 166 · see citing works
“In general, VNAs offer some advantages over classical antibodies such as ease to engineer, improved heat and pH stability, and better tissue penetration (Hamers-Casterman et al, 1993; van der Linden et al, 1999; Tillib et al, 2013).”
BackgroundSingle-Domain Antibodies As Therapeutics against Human Viral Diseases
Wu, Y., Jiang, S., & Ying, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01802 · Cited by 105 · see citing works
Single-Domain Antibodies and Their Formatting to Combat Viral Infections
Vlieger, D. D., Ballegeer, M., Rossey, I., Schepens, B., & Saelens, X. (2018) · Antibodies · doi:10.3390/antib8010001 · Cited by 94 · see citing works
Single-Domain Antibodies Targeting Neuraminidase Protect against an H5N1 Influenza Virus Challenge
Cardoso, F. M. L., Ibañez, L. I., den Hoecke, S. V., Baets, S. D., Smet, A., Roose, K., Schepens, B., Descamps, F. J., Fiers, W. C., Muyldermans, S., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03178-13 · Cited by 92 · see citing works
Zhao, J., Perera, R. A. P. M., Kayali, G., Meyerholz, D., Perlman, S., & Peiris, M. (2015) · Journal of Virology · doi:10.1128/jvi.00446-15 · Cited by 68 · see citing works
Novel Therapy Based on Camelid Nanobodies
Unciti-Broceta, J. D., del Castillo-Santaella, T., Soriano, M., Magez, S., & Garcia-Salcedo, J. A. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.87 · Cited by 50 · see citing works
Engineered bacteria as an orally administered anti-viral treatment and immunization system
Kamble, N. S., Thomas, S. C., Madaan, T., Ehsani, N., Sange, S., Tucker, K., Muhumure, A., Kunkler, S., & Kotagiri, N. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2500056 · Cited by 39 · see citing works
Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy
Stanova, A. K., Ryabkova, V. A., Tillib, S. V., Utekhin, V. J., Churilov, L. P., & Shoenfeld, Y. (2020) · Antibodies · doi:10.3390/antib9020019 · Cited by 30 · see citing works
Self-citationMolecular analysis of heavy chain-only antibodies of Camelus bactrianus
Tillib, S. V., Vyatchanin, A. S., & Muyldermans, S. (2014) · Biochemistry (Moscow) · doi:10.1134/s000629791412013x · Cited by 30 · see citing works
Self-citationTherapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update
Bhattacharya, M., Chatterjee, S., Lee, S., & Chakraborty, C. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.12.284 · Cited by 28 · see citing works
Towards improving clinical management of Middle East respiratory syndrome coronavirus infection
Hayden, F. G., Farrar, J., & Peiris, M. J. S. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70793-5 · Cited by 27 · see citing works
Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons
Rizk, S. S., Moustafa, D. M., ElBanna, S. A., El‐Din, H. T. N., & Attia, A. S. (2024) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-024-03990-4 · Cited by 26 · see citing works
Tillib, S. V., Privezentseva, M. E., Ivanova, T. I., Vasilev, L. F., Efimov, G. A., Gursky, Y. G., Georgiev, G. P., Goldman, I. L., & Садчикова, Е. Р. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.12.034 · Cited by 22 · see citing works
Self-citationVerma, V., Sinha, N., & Raja, A. (2025) · mAbs · doi:10.1080/19420862.2025.2486390 · Cited by 21 · see citing works
Sadavarte, R., Spearman, M. A., Okun, N., Butler, M., & Ghosh, R. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25193 · Cited by 21 · see citing works
Nanobodies—Useful Tools for Allergy Treatment?
Flicker, S., Zettl, I., & Tillib, S. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576255 · Cited by 21 · see citing works
Self-citationVoronina, D. V., Shcheblyakov, D. V., Favorskaya, I. A., Esmagambetov, I. B., Dzharullaeva, A. S., Ильдарович, Т. А., Zubkova, O. V., Popova, O. D., Kan, V. Y., Сергеевна, Б. А., et al. (2022) · Viruses · doi:10.3390/v14112485 · Cited by 21 · see citing works
Self-citationEgorova, D. A., Sv, T., Shcheblyakov, D. V., Dolzhikova, I. V., Щербинин, Д. Н., Zubkova, O. V., Ivanova, T. I., Ильдарович, Т. А., Шмаров, М. М., Logunov, D. Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150958 · Cited by 19 · see citing works
Self-citationSingle-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections
Huang, K., Ying, T., & Wu, Y. (2022) · Viruses · doi:10.3390/v14061162 · Cited by 18 · see citing works
Prospective Applications of Single-Domain Antibodies in Biomedicine
Tillib, S. V. (2020) · Molecular Biology · doi:10.1134/s0026893320030164 · Cited by 17 · see citing works
Self-citationDevelopment of a broad-spectrum therapeutic Fc-nanobody for human noroviruses
Hansman, G. S., Kher, G. M., Svirina, A. D., Tame, J. R. H., Hartley‐Tassell, L. E., Irie, H., Haselhorst, T., von Itzstein, M., Rudd, P. A., & Pancera, M. (2024) · Journal of Virology · doi:10.1128/jvi.00707-24 · Cited by 16 · see citing works
Isolation of nanobodies with potential to reduce patients' IgE binding to Bet v 1
Zettl, I., Ivanova, T. I., Strobl, M. R., Weichwald, C., Goryainova, O. S., Khan, E., Rutovskaya, M. V., Focke‐Tejkl, M., Drescher, A., Bohle, B., et al. (2021) · Allergy · doi:10.1111/all.15191 · Cited by 16 · see citing works
Self-citationПерспективы использования однодоменных антител в биомедицине
Tillib, S. V. (2020) · Molecular Biology · doi:10.31857/s0026898420030167 · Cited by 15 · see citing works
Self-citationGaras, М. N., Tillib, S. V., Zubkova, O. V., Рогожин, В. Н., Ivanova, T. I., Vasilev, L. A., Logunov, D. Y., Шмаров, М. М., Леонидовна, Т. И., Esmagambetov, I. B., et al. (2014) · Acta Naturae · doi:10.32607/20758251-2014-6-2-95-105 · Cited by 14 · see citing works
Self-citationHarmsen, M. M., Blokker, J., Pritz-Verschuren, S. B. E., Bartelink, W., der Burg, H. V., & Koch, G. (2013) · Antibodies · doi:10.3390/antib2020168 · Cited by 14 · see citing works
Influenza prevention and treatment by passive immunization.
Kalenik, B., Sawicka, R., Góra‐Sochacka, A., & Sirko, A. (2014) · Acta Biochimica Polonica · doi:10.18388/abp.2014_1879 · Cited by 13 · see citing works
Goryainova, O. S., Ivanova, T. I., Rutovskaya, M. V., & Tillib, S. V. (2017) · Molecular Biology · doi:10.1134/s0026893317060073 · Cited by 12 · see citing works
Self-citationSmall but Mighty: Nanobodies in the Fight Against Infectious Diseases
Jiang, W., Huang, C., Muyldermans, S., & Jia, L. (2025) · Biomolecules · doi:10.3390/biom15050610 · Cited by 11 · see citing works
Yep, A. T., Takeuchi, Y., Engelhardt, O. G., & Hufton, S. E. (2021) · Biomolecules · doi:10.3390/biom11030407 · Cited by 12 · see citing works
Single domain antibodies from camelids in the treatment of microbial infections
Greve, H. D., & Fioravanti, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1334829 · Cited by 9 · see citing works
Nanobodies in the limelight: Multifunctional tools in the fight against viruses
Moliner-Morro, A., McInerney, G. M., & Hanke, L. (2022) · Journal of General Virology · doi:10.1099/jgv.0.001731 · Cited by 8 · see citing works
Next generation single-domain antibodies against respiratory zoonotic RNA viruses
Swart, I. C., Gelder, W. V., de Haan, C. A. M., Bosch, B., & Oliveira, S. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1389548 · Cited by 7 · see citing works
Promises and challenges of single-domain antibodies to control influenza
Matthys, A., & Saelens, X. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105807 · Cited by 7 · see citing works
Tillib, S. V., & Goryainova, O. S. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924050134 · Cited by 5 · see citing works
Self-citationTrimeric Bet v 1-specific nanobodies cause strong suppression of IgE binding
Bauernfeind, C., Zettl, I., Ivanova, T. I., Goryainova, O. S., Weijler, A. M., Pranz, B., Drescher, A., Focke‐Tejkl, M., Pavkov‐Keller, T., Eckl‐Dorna, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343024 · Cited by 5 · see citing works
Self-citationBioorthogonal Labeling of Cellular Proteins by Enzymatic and Related Mechanisms
Walper, S. A., Turner, K. B., & Medintz, I. L. (2017) · Wiley eBooks · doi:10.1002/9783527683451.ch7 · Cited by 5 · see citing works
Single-Domain Antibodies—Novel Tools to Study and Treat Allergies
Zettl, I., Bauernfeind, C., Kollárová, J., & Flicker, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147602 · Cited by 4 · see citing works
Koroleva, E. A., Goryainova, O. S., Ivanova, T. I., Rutovskaya, M. V., Zigangirova, N. А., & Tillib, S. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042047 · Cited by 4 · see citing works
Self-citationH1N1 nanobody development and therapeutic efficacy verification in H1N1-challenged mice
Hwang, J., Jang, I.-Y., Bae, E., Choi, J., Kim, J. H., Lee, S. B., Kim, J., Lee, J. P., Jang, H. Y., Kim, H. T., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116781 · Cited by 3 · see citing works
Nanobodies: Diagnostic and Therapeutic Antibody Fragments
Karakaş, N., Öztürk, İ., Tosyalı, S., & Bay, S. (2018) · Acta Oncologica Turcica · doi:10.5505/aot.2018.28190 · Cited by 3 · see citing works
Voronina, D. V., Сергеевна, Б. А., Dzharullaeva, A. S., Popova, O. D., Kan, V. Y., Esmagambetov, I. B., Favorskaya, I. A., Shcheblyakov, D. V., Naroditskiy, B. S., & Al, G. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.29.510074 · Cited by 3 · see citing works
Antiviral potential of nanomaterials: Novel solutions for emerging challenges
Azab, W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821637-8.00003-1 · Cited by 2 · see citing works
Tillib, S. V., Morgunova, E. Y., Ivanova, T. I., Koroleva, E. A., Rutovskaya, M. V., & Zigangirova, N. A. (2017) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20176305461 · Cited by 2 · see citing works
Self-citationSingle-Domain Antibodies Used to Pretreat the Human Urinary Proteome in Cancer Biomarker Testing
Tillib, S. V., Goryainova, O. S., Sachko, A. M., Ivanova, T. I., Gaas, M. Y., Воробьев, Н. В., Каприн, А. Д., & Шегай, П. В. (2022) · Molecular Biology · doi:10.1134/s0026893322040124 · Cited by 1 · see citing works
Self-citationVorobyev, P. O., & Sv, T. (2023) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2023.005
Vorobyev, P. O., & Sv, T. (2023) · Вестник Российского государственного медицинского университета · doi:10.24075/vrgmu.2023.005
Tillib, S. V., & Goryainova, O. S. (2024) · Biochemistry (Moscow) · doi:10.31857/s0320972524050136
Self-citationNanobodies: a new frontier in influenza virus neutralization
Saadh, M. J., Abdulsahib, W. K., Bishoyi, A. K., Ballal, S., Singh, A., Saini, S., Abidov, K., Joshi, K. K., Kadheem, M., Jozpanahi, M., et al. (2025) · Folia Microbiologica · doi:10.1007/s12223-025-01303-2
VHH engineering and utilization for blood-brain barrier transport and anti-infectious diseases
Pérez, J. F., Asano, R., Uto, Y., Tsumoto, K., & Nakakido, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00069-8
Camelid VHHs as a Versatile Platform for Combating Viral Infections
Mufrrih, M., & Alandijany, T. A. (2026) · Pharmaceuticals · doi:10.3390/ph19091408
- Authors
- Tillib, S. V., Ivanova, T. I., Vasilev, L. A., Rutovskaya, M. V., Saakyan, S. A., Gribova, I. Y., Tutykhina, I. L., Sedova, E. S., Lysenko, A. A., Shmarov, M. M., Logunov, D. Y., Naroditsky, B. S., & Gintsburg, A. L.
- Affiliations
- Russian Academy of Sciences (RU)
- Gamalei Institute of Epidemiology and Microbiology (RU)
- Corresponding author
- Tillib, Sergei V.
- ORCID
- Venue
- Antiviral Research
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 97
- Issue
- 3
- Pages
- 245-254
- ISSN
- 0166-3542 (ISSN-L)
- OpenAlex
- W2089345618
- Cited by
- 54
- References
- 51
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 11 · 2023: 4 · 2022: 7 · 2021: 2 · 2020: 4 · 2018: 3 · 2017: 5 · 2016: 2 · 2015: 1 · 2014: 7 · 2013: 2
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Antiviral Research (publishedVersion)
- PubMed (publishedVersion)
- InTOR – Repository of the Institute "Torlak" (Institute of Virology, Vaccines and Sera “Torlak”, Belgrade, Serbia) (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- nanobodies, passive immunization, coiled-coil domain, phage display, virus neutralization, protective antibodies, intranasal administration, intraperitoneal administration, avian influenza
- MeSH terms
- Amino Acid Sequence, Animals, Antibodies, Viral, Camelus, Female, Humans, Immunologic Techniques, Influenza, Human, Mice, Inbred BALB C, Molecular Sequence Data, Protein Structure, Tertiary, Hemagglutinin Glycoproteins, Influenza Virus, Mice, Influenza A Virus, H5N2 Subtype, Single-Domain Antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
